{"title": "Vasomotor symptoms associated with menopause, Hot Flashes", "author": null, "url": null, "hostname": null, "description": "A study to learn more about how well elinzanetant works and how safe it is for the treatment of vasomotor symptoms (hot flashes) that are caused by hormonal ...", "sitename": "Vasomotor symptoms associated with menopause, Hot Flashes", "date": "2019-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Trial Condition(s):\nA study to learn more about how well elinzanetant works and how safe it is for the treatment of vasomotor symptoms (hot flashes) that are caused by hormonal changes over 52 weeks in women who have been through the menopause (OASIS-3)\n21810\nNot Available\nDie Forscher suchen nach einer besseren Methode zur Behandlung von Frauen, die nach der Menopause unter Hitzewallungen leiden. Hitzewallungen werden durch die hormonellen Ver\u00e4nderungen verursacht, die im K\u00f6rper einer Frau in der Menopause auftreten. Die Menopause ist der Zeitpunkt, an dem der Menstruationszyklus, auch Periode genannt, bei Frauen aufh\u00f6rt. Aufgrund des nat\u00fcrlichen Alterungsprozesses und der damit verbundenen hormonellen Umstellung produzieren die Eierst\u00f6cke w\u00e4hrend der Menopause immer weniger Sexualhormone. Der R\u00fcckgang der Hormonproduktion kann zu verschiedenen Symptomen f\u00fchren, die in manchen F\u00e4llen die Lebensqualit\u00e4t einer Frau in der Menopause stark beeintr\u00e4chtigen k\u00f6nnen.\nDie Studienbehandlung Elinzanetant wurde zur Behandlung von Symptomen entwickelt, die durch hormonelle Ver\u00e4nderungen verursacht werden. Es wirkt, indem es ein Protein namens Neurokinin daran hindert, Signale an andere Teile des K\u00f6rpers zu senden. Von Neurokinin wird angenommen, dass es eine gro\u00dfe Rolle bei der Ausl\u00f6sung von Hitzewallungen spielt. F\u00fcr Frauen, die die Menopause hinter sich haben, gibt es Medikamente gegen Hitzewallungen. Diese k\u00f6nnen jedoch bei manchen Frauen gesundheitliche Probleme verursachen.\nIn dieser Studie wollen die Forscher herausfinden, wie gut Elinzanetant im Vergleich zu einem Placebo bei solchen Frauen wirkt, die die Menopause hinter sich haben und unter Hitzewallungen leiden. Ein Placebo ist eine Behandlung, die wie ein Medikament aussieht, aber keinen Wirkstoff enth\u00e4lt. Um diese Studienbehandlungen zu vergleichen, werden die Teilnehmerinnen gebeten, Informationen \u00fcber ihre Hitzewallungen in einem elektronischen Tagebuch festzuhalten. Die Forscher untersuchen, wie h\u00e4ufig die Hitzewallungen bei den Teilnehmerinnen auftreten und wie stark sie sind. Sie werden die Ergebnisse vor der Behandlung und 12 Wochen nach der Behandlung auswerten.\nDie Teilnehmerinnen an dieser Studie nehmen einmal t\u00e4glich zwei Kapseln mit entweder Elinzanetant oder dem Placebo ein. Die Teilnehmer werden die Studienpr\u00e4parate 52 Wochen lang einnehmen.\nW\u00e4hrend der Studie werden die Teilnehmer etwa 11-mal ins Pr\u00fcfzentrum kommen und 2 telefonische Termine durchf\u00fchren. Die Teilnehmer verbleiben voraussichtlich f\u00fcr einen Zeitraum von 62 Wochen in der Studie.\nW\u00e4hrend der Studie werden die Teilnehmerinnen:\n\u2022 record information about their hot flashes in an electronic diary\n\u2022 answer questions about their symptoms\nDie \u00c4rzte werden:\n\u2022 check the participants\u2019 health\n\u2022 take blood samples\n\u2022 ask the participants questions about what medicines they are taking and if they are having adverse events\nEin unerw\u00fcnschtes Ereignis ist jedes medizinische Problem, das ein Teilnehmer w\u00e4hrend einer Studie hat. \u00c4rzte zeichnen alle unerw\u00fcnschten Ereignisse auf, die in Studien auftreten, selbst wenn sie nicht glauben, dass die unerw\u00fcnschten Ereignisse mit den Studienbehandlungen in Zusammenhang stehen.\n- Postmenopausal, defined as: a. at least 12 months of spontaneous amenorrhea prior to signing of informed consent, or b. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL and a serum estradiol concentration of < 30 pg/mL, or c. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels > 40 mIU/mL and a serum estradiol concentration of < 30 pg/mL, or d. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent. - Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition. - Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit and is showing eligibility with respect to previous inclusion criterion during this time period.\n- Any clinically significant prior or ongoing history of arrhythmias, heart block and QT prolongation either determined through clinical history or on ECG evaluation. - Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome. - Current or history (except complete remission for 5 years or more) of any malignancy (except basal and squamous cell skin tumors). Women receiving adjuvant endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study. - Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if they are medically cleared prior to study participation. - Untreated hyperthyroidism or hypothyroidism. -- Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for > 6 months before signing of informed consent is acceptable. -- Treated hypothyroidism with normal thyroid function test results during screening and a stable (for \u2265 3 months before signing of informed consent) dose of replacement therapy is acceptable. - Any unexplained post-menopausal uterine bleeding - Clinically relevant abnormal findings on mammogram. - Abnormal liver parameters. - Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial biopsy during screening.\n|Studienstandorte|\nStudienstandorte\nQueen Charlottes & Chelseas Hospital\nLondon, United Kingdom, W12 0NN\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nLiverpool Womens Hospital\nLiverpool, United Kingdom, L8 7SS\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nGlasgow Royal Infirmary | Haematology\nGlasgow, United Kingdom, G4 0SF\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSouthern Clinical Research Associates LLC\nMetairie, United States, 70001\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAdvances in Health, Inc.\nHouston, United States, 77030\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSuncoast Clinical Research Center, Inc.\nNew Port Richey, United States, 34652\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nParamount Research Solutions-College Park\nCollege Park, United States, 30349\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital de la Santa Creu i Sant Pau | Gynecology Department\nBarcelona, Spain, 8041\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital Sanitas La Zarzuela\nAravaca, Spain, 28023\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nH Univ. 12 de Octubre | Ginecolog\u00eda y Obstetricia\nMadrid, Spain, 28041\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSanos Clinic - Nordjylland\nGandrup, Denmark, 9362\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSanos Clinic - Syddanmark\nVejle, Denmark, 7100\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSanos Clinic - Herlev\nHerlev, Denmark, 2730\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMC Asklepii OOD\nDupnitza, Bulgaria, 2600\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMedical Center Panaceya\nSofia, Bulgaria, 1606\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMHAT Avis Medika\nPleven, Bulgaria, 5800\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMHAT Niamed\nStara Zagora, Bulgaria, 6000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMultiprofile Hospital for Activ Treatment Plovdiv\nPlovdiv, Bulgaria, 4000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSHOGAT Prof Dimitar Stamatov\nVarna, Bulgaria, 9000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMHAT Samokov\nSamokov, Bulgaria, 2000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nDCC Aleksandrovska\nSofia, Bulgaria, 1431\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHelix Biomedics, LLC\nBoynton Beach, United States, 33435\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUniversity of Florida College of Medicine\nJacksonville, United States, 32207\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nTidewater Physicians for Women\nNorfolk, United States, 23502\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nOffice of Dr. Edmond Pack\nLas Vegas, United States, 89113\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nPhysician Care Clinical Research\nSarasota, United States, 34239\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSeattle Clinical Research Center\nSeattle, United States, 98105\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMarvel Clinical Research, LLC\nHuntington Beach, United States, 92647\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nLas Vegas Clinical Trials, LLC\nNorth Las Vegas, United States, 89030\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSuncoast Clinical Research\nPalm Harbor, United States, 34684\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nWake Research, Inc.\nRaleigh, United States, 27612\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMesa Obstetricians and Gynecologists\nMesa, United States, 85206\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nVenus Gynecology, LLC former Magnolia OB/GYN Research Center\nMyrtle Beach, United States, 29572\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nClinical Research of Philadelphia, LLC\nPhiladelphia, United States, 19114\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nWomen's Health Texas\nKaty, United States, 77450\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nOffice of Dr. James A. Simon, MD\nWashington, United States, 20036\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nWomen's Health Texas\nKaty, United States, 77450\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nDavid I Lubetkin, MD, LLC\nBoca Raton, United States, 33486\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMobile Ob-Gyn, PC\nMobile, United States, 36608-6703\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nEastern Virginia Medical School | OB/GYN Clinical Research Center\nNorfolk, United States, 23507\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUT Health Women\u2019s Research Center at Memorial City\nHouston, United States, 77024\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nColumbus OB-GYN/Radiant Research\nColumbus, United States, 43213\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nEmpire Clinical Research\nPomona, United States, 91767\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCoastal Connecticut Research, LLC\nNew London, United States, 06320\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nJohns Hopkins Univ School Med|Johns Hopkins Hosp Dept Gyn/Ob\nBaltimore, United States, 21287\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nGabinet Ginekologiczny Janusz Tomaszewski\nBialystok, Poland, 15-244\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nVita Longa Sp. z o.o.\nKatowice, Poland, 40-748\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCentrum Medyczne Angelius Provita\nKatowice, Poland, 40-611\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nTwoja Przychodnia - Szczecinskie Centrum Medyczne\nSzczecin, Poland, 71-434\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCLINICAL MEDICAL RESEARCH Sp. z o. o.\nKatowice, Poland, 40-156\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCentrum Badawcze Wspolczesnej Terapii\nWarszawa, Poland, 02-679\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHospital Clinico Universitario | Gynecology and Obstetrics Department\nValencia, Spain, 46010\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nInstituto Palacios de Salud y Medicina de la Mujer\nMadrid, Spain, 28009\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMAC Research Centre Blackpool\nBlackpool, United Kingdom\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAMR Las Vegas\nLas Vegas, United States, 89119\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nOttawa Hospital-Riverside Campus\nOttawa, Canada, K1H 7W9\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAlpha Recherche Clinique LB9\nQuebec, Canada, G2J 0C4\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nViable Clinical Research Corporation\nScarborough, Canada, M1P 2T7\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nManna Research (Ottawa)\nNepean, Canada, K2J 4A7\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nManna Research (Burlington North)\nBurlington, Canada, L7M 4Y1\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nManna Research (Montreal)\nPointe-Claire, Canada, H9R 4S3\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nManna Research (Quebec)\nLevis, Canada, G6W 0M5\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUZ Gent\nGENT, Belgium, 9000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUZ Leuven Gasthuisberg\nLEUVEN, Belgium, 3000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCHR de la Citadelle - Department of Gynaecology & Obstetrics\nLIEGE, Belgium, 4000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nCHU Saint-Pierre/UMC Sint-Pieter\nBRUXELLES - BRUSSEL, Belgium, 1000\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nFemicare vzw\nTienen, Belgium, 3300\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nL\u00e4\u00e4k\u00e4rikeskus Gyneko\nOulu, Finland, 90100\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHUS / Naistenklinikka\nHelsinki, Finland, 00029\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMehil\u00e4inen Kuopio\nKuopio, Finland, 70100\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nTerveystalo Tampere\nTampere, Finland, 33100\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nH Univ. Virgen Roc\u00edo | Ginecolog\u00eda\nSevilla, Spain, 41013\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nPihlajalinna L\u00e4\u00e4k\u00e4rikeskus Oy, Savo-Karjala\nJoensuu, Finland, 80100\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nNational Institute of Clinical Research - Garden Grove\nGarden Grove, United States, 92844\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSouthern Clinical Research, LLC\nZachary, United States, 70791\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nInvestigators Research Group, LLC\nBrownsburg, United States, 46112\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nBoeson Research - Missoula\nMissoula, United States, 59804\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMHAT for Women's Health - Nadezhda OOD\nSofia, Bulgaria, 1330\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSpec. Hospital for Active Treatment of Oncological Diseases\nSofia, Bulgaria, 1233\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMaximos Ob/Gyn\nLeague City, United States, 77573\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nMAC Research Centre - Manchester\nManchester, United Kingdom\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nBoeson Research - Great Falls OBGYN\nGreat Falls, United States, 59405\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nHWC Women\u2019s Research Center\nEnglewood, United States, 45322\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nSpec.Hospital for obstetrics and gynecology Selena OOD\nPlovdiv, Bulgaria, 4002\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nA double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women\nTrial Type:\nInterventional\nIntervention Type:\nDrug\nTrial Purpose:\nTreatment\nAllocation:\nRandomized\nBlinding:\nN/A\nAssignment:\nParallel Assignment\nTrial Arms:\n2", "language": null, "image": "https://clinicaltrials.bayer.com/images/clinical_trials_explorer_logo.png", "pagetype": "website", "links": ["/", "/why-participate", "/#enhancingDiversity", "/what-are-clinical-trials", "/what-to-expect", "/transparency-policy", "https://www.facebook.com/sharer/sharer.php?u=", "https://twitter.com/share?url=", "https://www.linkedin.com/shareArticle?mini=true&url=", "/cdn-cgi/l/email-protection#f8c78b8d9a929d9b8cc5ba99819d8ad88b8c8d9c81d89796d8b59d969788998d8b9dd4d8ae998b9795978c978ad88b8195888c97958bd8d0b0978cd89e94998b909d8bd1de999588c39a979c81c5b1d8928d8b8cd89e978d969cd88c90998cd8ba99819d8ad890998bd899d88b8c8d9c81d89e978ad8889d9788949dd88f918c90d8b59d969788998d8b9dd4d8ae998b9795978c978ad88b8195888c97958bd8d0b0978cd89e94998b909d8bd1ddc8bcddc8b9a1978dd89b9996d8949d998a96d895978a9dd89a81d89b94919b9391969fd89796d88c909dd894919693d89a9d94978fd6d8", "https://clinicaltrials.gov/ct2/show/?term=NCT05030584&rank=1", "https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000059-38", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "https://www.facebook.com/pharma.bayer/", "https://twitter.com/bayerpharma", "https://www.youtube.com/bayerpharma", "/terms-use", "/privacy-statement", "/contact-us", "/transparency-policy", "/sitemap"]}